Constraints for symptomatic radiation pneumonitis of helical tomotherapy hypofractionated simultaneous multitarget radiotherapy for pulmonary metastasis from hepatocellular carcinoma.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 28314468.
- Also identified by DOI 10.1016/j.radonc.2017.02.015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study was aimed to identify the clinical and dosimetric parameters that predict symptomatic radiation pneumonitis (SRP, radiation pneumonitis≥2 grade) in patients with pulmonary metastasis from hepatocellular carcinoma (HCC) after helical tomotherapy (HT) hypofractionated simultaneous multitarget radiotherapy. 62 patients with 407 pulmonary metastases from HCC were consecutively treated with HT. The median radiation dose was a 49.7Gy in 4.0Gy/fraction to 95% of the planning target volume (PTV). The associations between the clinical and dosimetric data and incidences of SRP were analyzed. The dose-pneumonitis relationship was analyzed based on Biologically Effective Dose (BED). Univariate analysis showed that the gross tumor volume (GTV), PTV, median lung dose (MLD), the number of pulmonary metastatic lesions (NPML), and the percentage of non-target normal lung (NTNL) volume receiving more than a BED of 3-50Gy (V<sub>BED3-50</sub>) were associated with SRP. Multivariate logistic regression analysis showed that V<sub>BED20</sub> and NPML were significant parameters (both P<0.001) CONCLUSIONS: Our findings indicated that SRP can be predicted with NPML>5 and V<sub>BED20</sub>≥30.4% with the α/β ratio of 3Gy.
Medical subject headings
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Lung Neoplasms
- Radiation Dose Hypofractionation
- Radiation Pneumonitis
- Radiotherapy, Intensity-Modulated